- Home
- PLUS vs ZLAB Comparison
PLUS vs ZLAB Comparison
Compare PLUS & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUS
- ZLAB
- Stock Information
- Founded
- PLUS 1990
- ZLAB 2013
- Country
- PLUS United States
- ZLAB China
- Employees
- PLUS N/A
- ZLAB N/A
- Industry
- PLUS Retail: Computer Software & Peripheral Equipment
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- PLUS Technology
- ZLAB Health Care
- Exchange
- PLUS Nasdaq
- ZLAB Nasdaq
- Market Cap
- PLUS 2.6B
- ZLAB 1.8B
- IPO Year
- PLUS 1996
- ZLAB 2017
- Fundamental
- Price
- PLUS $96.76
- ZLAB $31.24
- Analyst Decision
- PLUS Hold
- ZLAB Strong Buy
- Analyst Count
- PLUS 1
- ZLAB 4
- Target Price
- PLUS $90.00
- ZLAB $52.50
- AVG Volume (30 Days)
- PLUS 100.1K
- ZLAB 976.3K
- Earning Date
- PLUS 11-05-2024
- ZLAB 11-12-2024
- Dividend Yield
- PLUS N/A
- ZLAB N/A
- EPS Growth
- PLUS N/A
- ZLAB N/A
- EPS
- PLUS 4.08
- ZLAB N/A
- Revenue
- PLUS $2,195,665,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- PLUS $5.69
- ZLAB $48.34
- Revenue Next Year
- PLUS $4.68
- ZLAB $47.12
- P/E Ratio
- PLUS $24.00
- ZLAB N/A
- Revenue Growth
- PLUS 0.56
- ZLAB 28.16
- 52 Week Low
- PLUS $53.54
- ZLAB $13.48
- 52 Week High
- PLUS $102.99
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- PLUS 52.65
- ZLAB 70.41
- Support Level
- PLUS $96.35
- ZLAB $31.52
- Resistance Level
- PLUS $99.25
- ZLAB $36.60
- Average True Range (ATR)
- PLUS 2.09
- ZLAB 1.36
- MACD
- PLUS -0.38
- ZLAB 0.34
- Stochastic Oscillator
- PLUS 28.23
- ZLAB 58.60
About PLUS ePlus inc.
ePlus Inc is a holding company. ePlus through its subsidiaries provides information technology solutions. The company's technology solutions enable organizations to optimize their IT environment and supply chain processes. It also provides consulting, professional and managed services, and complete lifecycle management services including flexible financing solutions. ePlus focuses on selling to medium and large enterprises in the United States and to customers in select international markets including the United Kingdom, the European Union, India, Singapore and Israel.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.